Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway

As a newly approved oral hypoglycaemic agent, the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin, which is derived from the natural product phlorizin can effectively reduce blood glucose. Recent clinical studies have found that dapagliflozin alleviates non-alcoholic fatty liver disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Liuran, Li, Qinghua, Huang, Wenbin, Han, Yibing, Tan, Huiting, An, Min, Xiang, Qianru, Zhou, Rui, Yang, Li, Cheng, Yanzhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176308/
https://www.ncbi.nlm.nih.gov/pubmed/34093169
http://dx.doi.org/10.3389/fphar.2021.589273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176308/
https://www.ncbi.nlm.nih.gov/pubmed/34093169
http://dx.doi.org/10.3389/fphar.2021.589273

Ejemplares similares